Initial management of children with newly diagnosed idiopathic thrombocytopenic purpura in the Nordic countries.
OBJECTIVE
To describe the management practices of newly diagnosed childhood idiopathic thrombocytopenic purpura (ITP) in the Nordic countries.


METHODS
A prospective registration was done from 1998 to 2000, including all children with newly diagnosed ITP aged 0-14 years and at least one platelet count < 30 x 10(9)/L.


RESULTS
506 children from 98 departments were registered. A diagnostic bone marrow aspiration was obtained within 14 days in 33%. Platelet and/or red blood cell transfusion was given in 11%. 287 children (57%) received platelet-enhancing therapy with intravenous immune globulin (IVIG) or corticosteroids within 14 days of diagnosis, IVIG being the first line choice in over 90% of the cases. There were noticeable national differences in the management. The decision to start drug treatment within two days of diagnosis was influenced mainly by the platelet count. Neither early treatment nor response to treatment changed the risk of chronic disease.


CONCLUSIONS
This study has shown a great variation in the management practices of children with newly diagnosed ITP. Prospective studies are required to produce evidence-based recommendations for this patient group.
Treutiger
Iris
I
Paediatric Department of Sachs' Children's Hospital, Stockholm, Sweden. iris.treutiger@sos.ki.se
Rajantie
Jukka
J
Zeller
Bernward
B
Elinder
Göran
G
Rosthöj
Steen
S
NOPHO ITP Working Group
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003718:Denmark; D005387:Finland; D006801:Humans; D007055:Iceland; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007223:Infant; D009664:Norway; D011446:Prospective Studies; D011696:Purpura, Thrombocytopenic / Q000175:diagnosis / Q000188:drug therapy*; D013548:Sweden
D000305:Adrenal Cortex Hormones; D016756:Immunoglobulins, Intravenous